CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, Inc. is the company identified by ticker CASIF on this research page. Use the overview to review the business, financial results, valuation and related news.

CASI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, focusing on the development and commercialization of therapeutic and pharmaceutical products across the People's Republic of China, the United States, and international territories. The company's offerings include EVOMELA, an intravenous formulation of melphalan, which serves as a conditioning treatment before stem cell transplantation and as palliative care for patients with multiple myeloma. Its hematology/oncology pipeline is robust, featuring CNCT19, an investigative autologous CD19 CAR-T product; BI-1206, a novel anti-FcγRIIB antibody designed for treating solid tumors and relapsed/refractory non-Hodgkin lymphoma; CB-5339, an innovative VCP/p97 inhibitor targeting valosin-containing protein (VCP)/p97 pathways crucial for protein homeostasis, DNA damage response, and cellular stress in various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent with diverse indications, including its use as a conditioning regimen prior to certain allogeneic hematopoietic stem cell transplants. CASI Pharmaceuticals maintains licensing agreements with entities such as Juventas Cell Therapy Ltd., BioInvent International AB, Black Belt Therapeutics Limited, Cleave Therapeutics, Inc., and Acrotech Biopharma L.L.C., primarily for the development and commercialization of its commercial product, EVOMELA. The company was founded in 1991 and is headquartered in Beijing, People's Republic of China.

Check the CASIF quote and chart on the overview and Chart tabs. Confirm the quote time, currency and trading session before comparing prices; a research update time is not a quote timestamp.

The Forecast tab shows available analyst price targets for CASIF. Analyst targets are separate from BTI scores and valuation estimates. Missing targets are unavailable, and forecasts do not guarantee returns.

Review CASI Pharmaceuticals, Inc.'s investor-relations announcements for declared dividends, ex-dividend dates and payment dates. A missing or zero yield in a data feed alone does not establish the company's dividend policy.

Check the Earnings tab for available dates and reported results, then confirm the next announcement with CASI Pharmaceuticals, Inc.'s investor-relations calendar. Estimated dates may change.

Compare CASIF's Valuation and Financials tabs, including cash flow, growth assumptions and valuation multiples. BTI estimates depend on their inputs and are different from analyst price targets.

Review CASI Pharmaceuticals, Inc.'s latest company filings for business-specific risks, alongside debt, profitability, competition and valuation. A BTI score summarizes research and is not a personalized investment recommendation.